Anna B. Halpern

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

Daisuke Araki, Brent L. Wood, Megan Othus et al. · Journal of Clinical Oncology · 2015 · 385 citations · Full text

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

Yi Zhou, Megan Othus, Daisuke Araki et al. · Leukemia · 2016 · 187 citations · Full text

Hematological Malignancy, Residual Disease, Transplantation +12

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit

Anna B. Halpern, Eva Culakova, Roland B. Walter et al. · JAMA Oncology · 2016 · 86 citations · Full text

Age-related differences in disease characteristics and clinical outcomes in polycythemia vera

Brady L. Stein, Santosh L. Saraf, Urszula Sobol et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 83 citations

Hematological Malignancy, Immunohematology, Thrombosis +15

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Anna B. Halpern, Megan Othus, Emily M. Huebner et al. · Leukemia · 2018 · 49 citations · Full text

Phase 1/2, Hematological Malignancy, Oncology +8